10/533833

JC06 Rec'd PCT/PTO 03 MAY 2005 PTO/SB/08A (08-03)

Under the Paperwork Reduction Act of 1995, no persons are required to	U.S. Patent and Trader	mark Office; U.S. DEPARTMENT OF COMMERI tion unless it contains a valid OMB control numb	CE
Substitute for form 1449/PTO	Complete if Known		
	Application Number	Based on PCT/JP03/14101	_
INFORMATION DISCLOSURE	Filing Date	Intl. Filing 05 NOV 2003	_
	First Named Inventor	Masahiro KAJINO	_
STATEMENT BY APPLICANT	Art Unit	tba	_
(Use as many sheets as necessary)	Examiner Name	tba	
Sheet 1 of 2	Attorney Docket Number	3116 US0P	7

/John Mabry/ (05/13/2008)

Examine

				FDOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (F Anoun)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	A1	^{US-} 4,126,689	11/21/1978	Stefan Sanczuk, et al.	
	A2	^{US-} 4,791,120	12/13/1988	Bor-Sheng Lin, et al	
		US-			
		US-			
		US-			*
		US-			
		US-	+		
		US-			· .
		US-			
		US-			
		US-			1
		US-			
		US-	 		
		US-	 		

 	FOREIGN	PATENT DOCU	MENTS		
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages	Т
	Country Code ³ "Number ⁴ "Kind Code ⁵ (If known)	MM-DD-YYYY		Or Relevant Figures Appear	1
A3	WO 01/44297 A1	06/21/2001	Synaptic Pharmaceutical		
A4	EP 1255109 A1	11/06/2002	Takeda Chemical Industries		Г
A5	WO 00/02919	01/20/2000	Merck & Co., Inc.		Г
 A6	EP 1237001 A1	09/04/2002	Takeda Chemical Industries		Г
A7	JP 01-213279 - Abstract	08/28/1989	BOC Group, Inc.		Γ
					Г

Date Considered Signature "EXAMINER Initial if reference considered, whether or not clasion is in conformance with MPEP 669. Draw line through clastics if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique clastion designation number (optional). See Kinds Codes of USPTO Patriot Communication and the state of the communication to applicant's unique clastion designation number (optional). See Kinds Codes of USPTO Patriot Communication is unique control on the state of the Communication of the state of the Period of the See of the region of the state of t

Translation is attached. Immission is attorious.

Immission is required to produce the control of the production of the production is attorious.

Immission is an application. Condendately is governed by \$8 U.S.C. 120 and 17 CRT 14.1 into condend is estimated to take 2 hours to compute, including attending, preparing, and submitting the completed application from to the USPTO. Time well very depending upon the individual case. Any comments on the amount of them you require to complete this form and/or subgreated to the production of the use of the production of the use of the production of the use of

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/533833

JC06 Rec'd PCT/PTO 03 MAY 2005

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Leadington of Information unlarge it contains a world DMB control united to the contr

Under the Paperwork Red	uction A	ct of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number.
Substitute for form 1449/PTO		Complete if Known		
			Application Number	Based on PCT/JP03/14101
INFORMATION DISCLOSURE			Filing Date	Intl. Filing 05 NOV 2003
STATEMENT BY APPLICANT		First Named Inventor	Masahiro KAJINO	
(Use as many sheets as necessary)			Art Unit	tba
(osc as many should as necessary)		Examiner Name	tba	
Sheet 2	of	2	Attorney Docket Number	3116 US0P

Comments on the	0.4	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A8	L.V. KUDZMA, et al., "4-Phenyl- and 4-Heteroaryl-4-anilidopiperidines. A Novel Class of Analgesic and Anesthetic Agents", J. Med. Chem., (1989, pp. 2534-2542, Vol. 32.	
	A9	N. SAKURA, et al., "StructureActivity Relationships of Neuromedin U. IV. Absolute Requirement of the Arginine Residue at Position 7 of Dog Neuromedin U-8 for Contractile Activity", Chem. Pharm. Bull., (2000), pp. 1166-1170, vol. 48, No. 8.	
	A10	M.J. COLEMAN, et al., "A Convenient Method for the N-Acylation and Esterification of Hindered Amino Acids: Synthesis of Ultra Short Acling Opiod Agonist, Remifentanii", Synlett, (1999), pp. 1923-1224, No. 12.	
	A11	N. MINAMINO, et al., "Neuromedin U-8 and U-25: Novel Uterus Stimulating and Hypertensive Peptides Identified in Porcine Spinal Cord", Biochemical and Biophysical Research Communications, (1985), pp. 1078-1085, Vol. 130, No. 3.	
	A12	L.K. MALENOWICZ, et al., "Effects of Neuromedin U-8 on the Rat Pituitary-Adrenocortical Axis", in vivo, (1993), pp. 419-422, Vol. 7.	
	A13	D.R. Brown, et al., "Neuromedin U Octapeptide Alters Ion Transport in Porcine Jejunum", European Journal of Pharmacology, (1988), pp. 159-162, Vol. 155.	
	A14	S. SUMI, et al., "Effect of Synthetic Neuromedin U-8 and U-25, Novel Peptides Identified in Porine Spinal Cord, on Splanchnic Circulation in Dogs", Life Sciences, (1987), pp. 1585-1590, Vol. 41.	
	A15	C.P. TAN, et al., "Cloning and Characterization of a Human and Murine T-Cell Orphan G-Protein-Coupled Receptor Similar to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1998), pp. 223-229, Vol. 52.	
	A16	K. K. McKEE, et al., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors". Genomics, (1997), pp. 426-434, Vol. 46.	

Examiner Signature	/John Mabry/ (05/13/2008)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Agolican's unique actions designation number (optional). 2 Agolican's its is place a check mark here if English lenguage Translation is stached.

This collection of Hormstonics in required by 35 U.S CH. 128. This inclination is restained be wind in 5th file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CPR 1.14. This collection is estimated to take 2 hours to complete, including sentency, pospering, and submitting the completed application from the USPTO. This well vary depending upon the including class. Any comments on the submitted of the completed application from the USPTO. This well vary depending upon the includical case. Any comments on the complete depending upon the included call case. Any comments on the Complete complete